JAK-IN-11
JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment[1]. JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
[916742-11-5]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Propanamide,_N-[[5-[[5-fluoro-4-[[4-_2-propyn-1-yloxy_phenyl]amino]-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]-.html
Purity
98.62
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
C#CCOC1=CC=C(NC2=NC(NC3=CC=C(C)C(S(=O)(NC(CC)=O)=O)=C3)=NC=C2F)C=C1
Molecular Formula
C23H22FN5O4S
Molecular Weight
483.52
References & Citations
[1]Daniel Magilavy, et al. 2,4 substituted pyrimidinediamines for use in discoid lupus. WO2012122452A1.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK
Available Sizes
Explore Other Products
Browse additional items from our catalog
Lentiviral human RECK shRNA (UAS) - Lentiviral human RECK shRNA (UAS, RFP) (25)
Tissue, Total Protein, Human Adult Normal, Ductus deferens
Tissue, Total Protein, Human Adult Normal, Ductus deferens
Lentiviral human GRM6 shRNA (UAS) - Lentiviral human GRM6 shRNA (UAS) (100)
